These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Effects of magnetic gemcitabine stealth nano-liposomes on the characteristics of breast cancer cell line MCF-7]. Tong Q; Shu XG; Lu XM; Li WY; Tao KX; Chen DD; Wang GB Yao Xue Xue Bao; 2009 Feb; 44(2):181-7. PubMed ID: 19408690 [TBL] [Abstract][Full Text] [Related]
7. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cosco D; Bulotta A; Ventura M; Celia C; Calimeri T; Perri G; Paolino D; Costa N; Neri P; Tagliaferri P; Tassone P; Fresta M Cancer Chemother Pharmacol; 2009 Oct; 64(5):1009-20. PubMed ID: 19263052 [TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives. Federico C; Morittu VM; Britti D; Trapasso E; Cosco D Int J Nanomedicine; 2012; 7():5423-36. PubMed ID: 23139626 [TBL] [Abstract][Full Text] [Related]
10. Tumor-specific delivery of gemcitabine with activatable liposomes. Tucci ST; Kheirolomoom A; Ingham ES; Mahakian LM; Tam SM; Foiret J; Hubbard NE; Borowsky AD; Baikoghli M; Cheng RH; Ferrara KW J Control Release; 2019 Sep; 309():277-288. PubMed ID: 31301340 [TBL] [Abstract][Full Text] [Related]
11. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? Tang M; Svirskis D; Leung E; Kanamala M; Wang H; Wu Z J Control Release; 2019 Jul; 305():89-100. PubMed ID: 31096017 [TBL] [Abstract][Full Text] [Related]
12. Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells. Han NK; Shin DH; Kim JS; Weon KY; Jang CY; Kim JS Int J Nanomedicine; 2016; 11():1413-25. PubMed ID: 27103799 [TBL] [Abstract][Full Text] [Related]
13. Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. Papa AL; Basu S; Sengupta P; Banerjee D; Sengupta S; Harfouche R BMC Cancer; 2012 Sep; 12():419. PubMed ID: 22998550 [TBL] [Abstract][Full Text] [Related]
14. Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes. Kim MJ; Lee HJ; Lee IA; Kim IY; Lim SK; Cho HA; Kim JS Arch Pharm Res; 2008 Apr; 31(4):539-46. PubMed ID: 18449514 [TBL] [Abstract][Full Text] [Related]
15. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models. Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188 [TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. Celano M; Calvagno MG; Bulotta S; Paolino D; Arturi F; Rotiroti D; Filetti S; Fresta M; Russo D BMC Cancer; 2004 Sep; 4():63. PubMed ID: 15363094 [TBL] [Abstract][Full Text] [Related]
18. A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging. Bornmann C; Graeser R; Esser N; Ziroli V; Jantscheff P; Keck T; Unger C; Hopt UT; Adam U; Schaechtele C; Massing U; von Dobschuetz E Cancer Chemother Pharmacol; 2008 Mar; 61(3):395-405. PubMed ID: 17554540 [TBL] [Abstract][Full Text] [Related]
19. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma. Braham MV; Deshantri AK; Minnema MC; Öner FC; Schiffelers RM; Fens MH; Alblas J Int J Nanomedicine; 2018; 13():8105-8118. PubMed ID: 30555229 [TBL] [Abstract][Full Text] [Related]
20. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells. Xu H; Paxton J; Lim J; Li Y; Zhang W; Duxfield L; Wu Z Pharm Res; 2014 Oct; 31(10):2583-92. PubMed ID: 24639234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]